JP7542257B2 - 可溶化された封入抗原を含むポリマーソーム、ならびにその作製および使用方法 - Google Patents

可溶化された封入抗原を含むポリマーソーム、ならびにその作製および使用方法 Download PDF

Info

Publication number
JP7542257B2
JP7542257B2 JP2020560590A JP2020560590A JP7542257B2 JP 7542257 B2 JP7542257 B2 JP 7542257B2 JP 2020560590 A JP2020560590 A JP 2020560590A JP 2020560590 A JP2020560590 A JP 2020560590A JP 7542257 B2 JP7542257 B2 JP 7542257B2
Authority
JP
Japan
Prior art keywords
seq
polymersome
antigen
peptide
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020560590A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512142A5 (enExample
JP2021512142A (ja
Inventor
マーダヴァン ナラニ
ファビアン デカイヨ
トーマス アンドリュー コーネル
アミット クマール カーン
Original Assignee
エイシーエム バイオラブズ プライベート リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エイシーエム バイオラブズ プライベート リミテッド filed Critical エイシーエム バイオラブズ プライベート リミテッド
Publication of JP2021512142A publication Critical patent/JP2021512142A/ja
Publication of JP2021512142A5 publication Critical patent/JP2021512142A5/ja
Priority to JP2024134738A priority Critical patent/JP2024160341A/ja
Application granted granted Critical
Publication of JP7542257B2 publication Critical patent/JP7542257B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020560590A 2018-01-25 2019-01-25 可溶化された封入抗原を含むポリマーソーム、ならびにその作製および使用方法 Active JP7542257B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024134738A JP2024160341A (ja) 2018-01-25 2024-08-13 可溶化された封入抗原を含むポリマーソーム、ならびにその作製および使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18153348.0 2018-01-25
EP18153348 2018-01-25
PCT/EP2019/051853 WO2019145475A2 (en) 2018-01-25 2019-01-25 Polymersomes comprising a soluble encapsulated antigen as well as methods of making and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024134738A Division JP2024160341A (ja) 2018-01-25 2024-08-13 可溶化された封入抗原を含むポリマーソーム、ならびにその作製および使用方法

Publications (3)

Publication Number Publication Date
JP2021512142A JP2021512142A (ja) 2021-05-13
JP2021512142A5 JP2021512142A5 (enExample) 2022-02-01
JP7542257B2 true JP7542257B2 (ja) 2024-08-30

Family

ID=61192649

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020560590A Active JP7542257B2 (ja) 2018-01-25 2019-01-25 可溶化された封入抗原を含むポリマーソーム、ならびにその作製および使用方法
JP2024134738A Pending JP2024160341A (ja) 2018-01-25 2024-08-13 可溶化された封入抗原を含むポリマーソーム、ならびにその作製および使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024134738A Pending JP2024160341A (ja) 2018-01-25 2024-08-13 可溶化された封入抗原を含むポリマーソーム、ならびにその作製および使用方法

Country Status (6)

Country Link
US (2) US12239736B2 (enExample)
EP (1) EP3743101A2 (enExample)
JP (2) JP7542257B2 (enExample)
CN (1) CN111954541A (enExample)
BR (1) BR112020013405A2 (enExample)
WO (1) WO2019145475A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104936579B (zh) * 2012-11-19 2020-02-07 新加坡科技研究局 用于引发对免疫原的免疫响应的方法
BR112022001185A2 (pt) * 2019-08-01 2022-03-15 Acm Biolabs Pte Ltd Método de eliciamento de uma resposta imune administrando uma população de polimerossomos tendo um antígeno associado com uma população de polimerossomos tendo um adjuvante associado, bem como composições compreendendo as duas populações de polimerossomos
US11642407B2 (en) * 2020-02-28 2023-05-09 Massachusetts Institute Of Technology Identification of variable influenza residues and uses thereof
WO2021214339A2 (en) 2020-04-24 2021-10-28 Acm Biolabs Pte Ltd Vaccine against human-pathogenic coronaviruses
JP2024500360A (ja) * 2020-12-11 2024-01-09 エイシーエム バイオラブズ プライベート リミテッド 関連づけられた抗原および関連づけられたアジュバントを有する２つのポリマーソーム集団を投与することによる、Ｔｈ１／Ｔｈ２免疫応答の調整方法
CN117597109A (zh) * 2021-02-02 2024-02-23 Acm 生物实验室私人有限公司 聚合物囊泡相关联的佐剂用于刺激免疫应答的单独使用
AU2022258552A1 (en) * 2021-04-12 2023-10-19 Acm Biolabs Pte Ltd Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof
CN113416788B (zh) * 2021-07-14 2022-04-29 兰州大学 一种与湖羊睾丸性状相关的adpgk基因分子标记及其应用
US20250295762A1 (en) * 2022-03-21 2025-09-25 The University Of North Carolina At Chapel Hill Composite bioactive compositions and applications thereof
WO2024081641A2 (en) * 2022-10-10 2024-04-18 Northwestern University Methods for preparing protein-conjugated nanocarriers
CN117045809B (zh) * 2023-09-27 2025-08-29 国家纳米科学中心 异种哺乳动物细胞来源的囊泡在制备疫苗载体中的应用
CN120860194A (zh) * 2025-07-15 2025-10-31 中国人民解放军总医院第一医学中心 一种流感病毒纳米疫苗及其制备方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007502780A (ja) 2003-08-21 2007-02-15 リポテック・プロプライエタリー・リミテッド ｉｎｖｉｖｏにおける樹状細胞の標的化
JP2016500071A (ja) 2012-11-19 2016-01-07 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 免疫原に対する免疫応答を惹起するための方法
WO2017151922A1 (en) 2016-03-02 2017-09-08 The Board Of Regents Of The University Of Texas System Sting activating nanovaccine for immunotherapy

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US569825A (en) 1896-10-20 John h
US633425A (en) 1899-01-26 1899-09-19 Louis Henry Clyborne Wire-tightener.
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
FR2766205B1 (fr) * 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
AU2007319836A1 (en) * 2006-11-14 2008-05-22 The Trustees Of The University Of Pennsylvania Efficient nuclear delivery of antisense oligonucleotides
US8323696B2 (en) 2008-08-29 2012-12-04 Ecole Polytechnique Federale De Lausanne Nanoparticles for immunotherapy
EP2601262A4 (en) * 2010-08-05 2014-01-22 Agency Science Tech & Res VESIGN STRUCTURE WITH SEVERAL CHAMBERS AND METHOD FOR THEIR EDUCATION
EP4218808A3 (en) 2012-03-12 2023-08-09 Advanced BioAdjuvants, LLC Adjuvant and vaccine compositions
US10017545B2 (en) * 2013-06-03 2018-07-10 University Of Maryland, College Park Compositions and vaccines comprising vesicles and methods of using the same
EP2898894A1 (en) 2014-01-27 2015-07-29 LTS LOHMANN Therapie-Systeme AG Nano-in-micro particles for intradermal delivery
WO2016055611A1 (en) * 2014-10-09 2016-04-14 Universität Basel Self-assembled nanostructures and methods of use thereof
US9636397B2 (en) 2015-03-24 2017-05-02 VaxLiant, LLC Adjuvant compositions and related methods

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007502780A (ja) 2003-08-21 2007-02-15 リポテック・プロプライエタリー・リミテッド ｉｎｖｉｖｏにおける樹状細胞の標的化
JP2016500071A (ja) 2012-11-19 2016-01-07 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 免疫原に対する免疫応答を惹起するための方法
WO2017151922A1 (en) 2016-03-02 2017-09-08 The Board Of Regents Of The University Of Texas System Sting activating nanovaccine for immunotherapy

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Biomaterials，2013年，Vol. 34, No. 17，p. 4339-4346，https://doi.org/10.1016/j.biomaterials.2013.02.024
Journal of Polymer Science Part B Polymer Physics，2016年，Vol. 54, No. 16，p. 1581-1592，https://doi.org/10.1002/polb.24059
Kuai, Rui et al.，Designer vaccine nanodiscs for personalaized cancer immunotherapy，nature materials，2016年12月26日，DOI: 10.1038/NMAT4822
ZHU, Guizhi et al.，Albumin/vaccine nanocomplexs that assemble in vivo for combination cancet immunotherapy，NATURE COMMUNICATIONS，2017年12月05日，8，1954，DOI: 10.1038/s4167-017-02191-y

Also Published As

Publication number Publication date
JP2024160341A (ja) 2024-11-13
CN111954541A (zh) 2020-11-17
BR112020013405A2 (pt) 2020-12-01
WO2019145475A2 (en) 2019-08-01
US20210251899A1 (en) 2021-08-19
US20250186346A1 (en) 2025-06-12
JP2021512142A (ja) 2021-05-13
US12239736B2 (en) 2025-03-04
WO2019145475A3 (en) 2019-09-06
EP3743101A2 (en) 2020-12-02

Similar Documents

Publication Publication Date Title
JP7542257B2 (ja) 可溶化された封入抗原を含むポリマーソーム、ならびにその作製および使用方法
JP7676030B2 (ja) 関連づけられた抗原を有するポリマーソームの集団を、関連づけられたアジュバントを有するポリマーソームの集団と一緒に投与することによって、免疫応答を誘発する方法、およびそれら２つのポリマーソーム集団を含む組成物
JP2022552552A (ja) 活性薬剤または治療剤の送達のための水中油型エマルジョン製剤
US20250281405A1 (en) Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof
US20220105176A1 (en) Polymersomes comprising a covalently bound antigen as well as methods of making and uses thereof
JP7127021B2 (ja) 細胞傷害性粒子
US20230398207A1 (en) Modulating th1/th2 immune response by administering two populations of polymersomes having an associated antigen and an associated adjuvant
US20240108720A1 (en) Sole use of polymersome associated adjuvant for stimulating an immune response
JP2025508798A (ja) 脂質とブロックコポリマーとを含むポリマー－脂質ハイブリッドナノ粒子ならびにその作製方法および使用方法
US20230381309A1 (en) Methods of treating diffuse large b-cell lymphoma
AU2021392036A9 (en) Method of sensitizing cancers to immunotherapy using immunomodulatory agents
JP7086000B2 (ja) 体液性親和性の加速に関する方法及び組成物
WO2024186623A1 (en) Methods of making dried pharmaceutical compositions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200731

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230301

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230831

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240404

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240716

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240813

R150 Certificate of patent or registration of utility model

Ref document number: 7542257

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150